Pharma giant Lilly strengthens ties with Insilico Medicine to accelerate AI-driven drug development and reshape discovery timelines.
Insilico Medicine has announced a new research and licensing collaboration with Eli Lilly, expanding an existing relationship that dates back to 2023. The agreement will see Insilico’s Pharma.AI platform combined with Lilly’s disease expertise to discover and advance therapeutic candidates across a range of indications.
Under the deal, Insilico will deploy its generative AI systems to generate, design and optimize compounds against targets defined by Lilly. Financial terms could exceed $100 million, including an upfront payment, milestones and tiered royalties on eventual commercial sales.
Insilico describes the partnership as both a continuation and a deepening of its existing licensing arrangement with Lilly – a sign that large pharmaceutical companies are increasingly willing to integrate external AI technologies directly into their R&D pipelines rather than simply observe from the sidelines.
Accelerating the path from idea to candidate
Founded in 2014, Insilico has built a reputation for coupling AI with automated wet labs to reduce the time and cost of early-stage drug discovery. The company reports that between 2021 and 2024 it nominated 20 preclinical candidates, with an average turnaround of 12 to 18 months from project initiation to preclinical candidate stage – compared with the industry’s usual three to six years. Each program, according to Insilico, required the synthesis and testing of only 60 to 200 molecules.
Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine, said the partnership builds on a longstanding relationship and reflects growing industry recognition of AI’s potential to reshape R&D.
“We are delighted to collaborate with Lilly, a global leader in the pharmaceutical industry, renowned for its commitment to medical innovation,” he said. “Lilly has been a valued user of our Pharma.AI software suite, and this expanded collaboration further recognizes Insilico’s AI-driven drug discovery capabilities while strengthening our longstanding partnership. By joining forces, we are accelerating the development of transformative therapies to address urgent patient needs worldwide.”
Longevity.Technology: Big Pharma is no longer just dipping a toe in the AI waters – it’s diving in, algorithms and all. Lilly’s expanded collaboration with Insilico marks yet another instance of a pharmaceutical heavyweight acknowledging that the traditional R&D model simply can’t keep pace with the computational revolution reshaping discovery. For longevity biotech, this represents both validation and acceleration; AI isn’t merely speeding the process, it’s redrawing the map. The irony, of course, is that while longevity start-ups talk about disruption, it’s the entrenched giants – with their budgets, data and pipelines – who may be the ones to turn ambition into approved therapies. Still, partnerships like this suggest that the boundary between pharma and longevity biotech is becoming increasingly permeable – and that’s precisely what’s needed if the science of aging is to evolve into the business of healthspan.
From algorithms to age-related applications
While the agreement does not focus explicitly on longevity or geroscience, the therapeutic areas cited by Insilico – including fibrosis, oncology, immunology, pain and metabolic disorders – are closely tied to the biology of aging and the company is clear its mission is “to extend healthy productive longevity for everyone by transforming drug discovery and development with generative artificial intelligence.” Many of these pathways are implicated in age-related decline, and advances in their modulation have the potential to improve healthspan as well as lifespan.
Indeed, just last week Insilico revealed a portfolio of cardiometabolic programs geared around oral small molecules and including GLP-1 receptor agonists designed for improved safety and pharmacokinetics; the company argued that such cardiometabolic and anti-obesity drugs “may be the first wave of longevity therapeutics increasing both healthspan and lifespan in a large population”. This deal with Lilly therefore sits neatly into a broader strategic pivot in which metabolic optimization – long the silent under-writer of aging processes – is finally being treated as a front-line target rather than a secondary concern.
The partnership also highlights a wider shift in the biotech ecosystem. As AI platforms demonstrate their ability to generate high-quality candidates quickly, pharmaceutical companies are beginning to view these collaborations as strategic necessities rather than speculative experiments. The result is a blurring of boundaries between discovery-stage biotech and late-stage development – a continuum in which computational biology, automation and translational science meet.
Momentum in a transforming landscape
For the longevity sector, this alignment between Big Pharma and AI biotech may prove pivotal. It signals growing confidence in computational methods as enablers of faster, more predictive discovery – tools capable of tackling the complexity inherent in age-associated disease. It also highlights that the infrastructure, capital and regulatory experience of large pharmaceutical companies will likely remain essential to bringing geroscience-driven therapeutics to market.
The long view
AI will not replace biology, but it is already redefining how biology is explored. As collaborations such as this one mature, they are likely to shorten the distance between insight and intervention, allowing therapies aimed at the mechanisms of aging to move from concept to clinic with unprecedented efficiency. For an industry still learning to measure time not just in years of life, but in years of health, that may be the most transformative outcome of all.
